Literature DB >> 8328984

Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. In vitro and in vivo quantitative characterization.

L Raveh1, J Grunwald, D Marcus, Y Papier, E Cohen, Y Ashani.   

Abstract

Butyrylcholinesterase purified from human plasma (HuBChE) was evaluated both in vitro and in vivo in mice and rats as a single prophylactic antidote against the lethal effects of highly toxic organophosphates (OP). The variation among the bimolecular rate constants for the inhibition of HuBChE by tabun, VX, sarin, and soman was 10-fold (0.47 to 5.12 x 10(7) M-1 min-1; pH 8.0, 26 degrees). The half-life of HuBChE in blood after its i.v. administration in mice and rats was 21 and 46 hr, respectively. The peak blood-enzyme level was obtained in both species approximately 9-13 hr following i.m. injection of HuBChE, and the fraction of the enzyme activity absorbed into the blood was 0.9 and 0.54 for rats and mice, respectively. The stoichiometry of the in vivo sequestration of the anti-cholinesterase toxicants was consistent with the HuBChE/OP ratio of the molar concentration required to inhibit 100% enzyme activity in vitro. Linear correlation was demonstrated between the blood level of HuBChE and the extent of protection conferred against the toxicity of nerve agents. Pretreatment with HuBChE alone was sufficient not only to increase survivability following exposure to multiple median lethal doses of a wide range of potent OPs, but also to alleviate manifestation of toxic symptoms in mice and rats without the need for additional post-exposure therapy. It appeared that in order to confer protection against lethality nerve agents had to be scavenged to a level below their median lethal dose LD50 within less than one blood circulation time. Since the high rate of sequestration of nerve agents by HuBChE is expected to underlie the activity of the scavenger in other species as well, a reliable extrapolation of its efficacy from experimental animals to humans can be made.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8328984     DOI: 10.1016/0006-2952(93)90228-o

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  28 in total

1.  Tetramerization domain of human butyrylcholinesterase is at the C-terminus.

Authors:  R M Blong; E Bedows; O Lockridge
Journal:  Biochem J       Date:  1997-11-01       Impact factor: 3.857

2.  Oxime-assisted acetylcholinesterase catalytic scavengers of organophosphates that resist aging.

Authors:  Rory Cochran; Jaroslaw Kalisiak; Tuba Küçükkilinç; Zoran Radic; Edzna Garcia; Limin Zhang; Kwok-Yiu Ho; Gabriel Amitai; Zrinka Kovarik; Valery V Fokin; K Barry Sharpless; Palmer Taylor
Journal:  J Biol Chem       Date:  2011-07-05       Impact factor: 5.157

3.  Effect of human acetylcholinesterase subunit assembly on its circulatory residence.

Authors:  T Chitlaru; C Kronman; B Velan; A Shafferman
Journal:  Biochem J       Date:  2001-03-15       Impact factor: 3.857

Review 4.  Acetylcholinesterase inhibition resulting from exposure to inhaled OP can be prevented by pretreatment with BChE in both macaques and minipigs.

Authors:  Yvonne Rosenberg; Ashima Saxena
Journal:  Neuropharmacology       Date:  2020-05-19       Impact factor: 5.250

Review 5.  Cholinesterases and the fine line between poison and remedy.

Authors:  Carey N Pope; Stephen Brimijoin
Journal:  Biochem Pharmacol       Date:  2018-01-31       Impact factor: 5.858

6.  Involvement of oligomerization, N-glycosylation and sialylation in the clearance of cholinesterases from the circulation.

Authors:  C Kronman; B Velan; D Marcus; A Ordentlich; S Reuveny; A Shafferman
Journal:  Biochem J       Date:  1995-11-01       Impact factor: 3.857

7.  Plant-derived human acetylcholinesterase-R provides protection from lethal organophosphate poisoning and its chronic aftermath.

Authors:  Tama Evron; Brian C Geyer; Irene Cherni; Mrinalini Muralidharan; Jacquelyn Kilbourne; Samuel P Fletcher; Hermona Soreq; Tsafrir S Mor
Journal:  FASEB J       Date:  2007-05-02       Impact factor: 5.191

8.  Intrathecal delivery of fluorescent labeled butyrylcholinesterase to the brains of butyrylcholinesterase knock-out mice: visualization and quantification of enzyme distribution in the brain.

Authors:  Noel D Johnson; Ellen G Duysen; Oksana Lockridge
Journal:  Neurotoxicology       Date:  2009-03-20       Impact factor: 4.294

9.  Partial purification and characterization of soluble isoform of butyrylcholinesterase from rat intestine.

Authors:  Ozlem Yildiz; Ebru Bodur; A Neşe Cokuğraş; Nazmi Ozer
Journal:  Protein J       Date:  2004-02       Impact factor: 2.371

10.  Modulation of circulatory residence of recombinant acetylcholinesterase through biochemical or genetic manipulation of sialylation levels.

Authors:  T Chitlaru; C Kronman; M Zeevi; M Kam; A Harel; A Ordentlich; B Velan; A Shafferman
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.